Technoderma reported Phase 2a results via press release/PRNewswire describing a 4-month, 71-participant, 1:1:1 randomized trial comparing two concentrations to placebo.
- Lab
- Phase 1
- Phase 2
- Phase 3
- Approved
Phase 2
How it works
Topical small molecule intended to activate dormant hair follicle stem cells and induce the anagen (growth) phase, similar regenerative rationale to PP405.
Results so far
Non-vellus target area hair count increased by 24.3 hairs (0.02% dose) and 20.3 hairs (0.0025% dose) vs 14 hairs for placebo; well tolerated with minimal to no systemic exposure (press-release figures).
What's next
No publicly stated Phase 3 timeline found in this research pass.
In India
No India-specific development identified.
Sources
- Company announcement ↗ (accessed 2026-10-17)
- News report ↗ (accessed 2026-10-17)
- Trial registry ↗ (accessed 2026-10-17)
What to do today: treatments in development aren't a reason to wait. Ask a dermatologist about the options that work now, such as minoxidil and, for men, finasteride.
Discussion
Share your experience or ask a question. New members' posts are reviewed before they appear.